Literature DB >> 18759809

Neuropsychological profile in bipolar disorder: a preliminary study of monotherapy lithium-treated euthymic bipolar patients evaluated at a 2-year interval.

M Mur1, M J Portella, A Martínez-Arán, J Pifarré, E Vieta.   

Abstract

OBJECTIVE: To investigate the cognitive impairment of a sample of euthymic bipolar patients treated with lithium monotherapy at baseline in a 2-year longitudinal study.
METHOD: Fifteen DSM-IV-TR bipolar out-patients and 15 healthy-matched controls were cognitively assessed twice over a 2-year follow-up. All patients underwent lithium monotherapy on the first evaluation, and they were euthymic in both evaluations. Cognitive assessment was performed by means of a neuropsychological test battery tapping into the main cognitive domains (executive function, attention, processing speed, verbal memory and visual memory).
RESULTS: Repeated measures multivariate analysis of variance showed that the bipolar disorder group was cognitively impaired in the executive domain, attention and processing speed, and such deficits were maintained over time.
CONCLUSION: Our results showed that executive dysfunction is the main long-term neuropsychological deficit of bipolar disorder. Also, the persistence of these deficits did not seem to be influenced by any clinical or pharmacological variables.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759809     DOI: 10.1111/j.1600-0447.2008.01245.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  8 in total

1.  Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design.

Authors:  Katherine E Burdick; Terence A Ketter; Joseph F Goldberg; Joseph R Calabrese
Journal:  J Clin Psychiatry       Date:  2015-03       Impact factor: 4.384

Review 2.  Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment.

Authors:  Ni Xu; Benjamin Huggon; Kate E A Saunders
Journal:  CNS Drugs       Date:  2020-01       Impact factor: 5.749

Review 3.  Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.

Authors:  Olivia O'Leary; Yvonne Nolan
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

Review 4.  The management of cognitive impairment in bipolar disorder: current status and perspectives.

Authors:  Marsal Sanches; Isabelle E Bauer; Juan F Galvez; Giovana B Zunta-Soares; Jair C Soares
Journal:  Am J Ther       Date:  2015 Nov-Dec       Impact factor: 2.688

5.  Early-onset bipolar disorder: how about visual-spatial skills and executive functions?

Authors:  Sara Lera-Miguel; Susana Andrés-Perpiñá; Rosa Calvo; Mar Fatjó-Vilas; Lourdes Fañanás; Fañanás Lourdes; Luisa Lázaro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-11-18       Impact factor: 5.270

6.  Neurocognitive dysfunction and psychosocial outcome in patients with bipolar I disorder at 15-year follow-up.

Authors:  K E Burdick; J F Goldberg; M Harrow
Journal:  Acta Psychiatr Scand       Date:  2010-12       Impact factor: 6.392

Review 7.  Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.

Authors:  Margaret K King; Marta Pardo; Yuyan Cheng; Kimberlee Downey; Richard S Jope; Eléonore Beurel
Journal:  Pharmacol Ther       Date:  2013-07-31       Impact factor: 12.310

8.  Joint analysis of cognitive and circadian variation in Schizophrenia and Bipolar I Disorder.

Authors:  Pramod Thomas; Fanyin He; Sati Mazumdar; Joel Wood; Triptish Bhatia; Ruben C Gur; Raquel E Gur; Daniel Buysse; Vishwajit L Nimgaonkar; Smita N Deshpande
Journal:  Asian J Psychiatr       Date:  2017-11-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.